Is AI a risk or an opportunity? Is regulatory divergence a barrier or a catalyst for innovation? The answer depends on how prepared and how agile your organisation is. As regulatory frameworks shift beneath our feet, the question facing every drug developer is not ‘if’ but ‘how’ these macro trends will disrupt their strategy. In today’s landscape, regulatory affairs is no longer a back-office function, it is a boardroom imperative.
Drawing on insights from recent industry forums and panel discussions, this article explores three macro trends that are redefining regulatory strategy: regulatory divergence, the integration of real-world evidence (RWE) and oversight of artificial intelligence (AI) and novel modalities. Each presents distinct challenges, but also opportunities for companies to differentiate through foresight, agility and strategic partnership.
1. Regulatory modernization and divergence
Core Challenge: Keeping pace with scientific innovation while managing growing regional divergence.
Global regulators are modernising at speed. Agencies such as the FDA, EMA, NMPA, CDSCO and MHRA are embracing adaptive pathways, rolling reviews and real-time data submissions. Yet, each market is evolving at its own pace, creating a tension between convergence and divergence. While ICH harmonisation efforts and joint reviews are expanding, regional protectionism and data localisation policies, particularly in China, India and Brazil are introducing friction and operational complexity.
What’s happening now:
The EU’s Pharma Package (2025) exemplifies this duality. It introduces modulated exclusivity (ranging from 8 to 12 years), supply resilience obligations and regulatory sandboxes for novel therapies. Simultaneously, it tightens rules around shortages and mandates in-EU manufacturing capacity. Meanwhile, the revised ICH E6(R3) Good Clinical Practice guideline, effective July 2025, shifts trial oversight toward risk-based, decentralised models, modernising standards globally but allowing for local interpretation.
Practical perspective:
Recent experience shows that divergence can create significant extra work for sponsors, especially when local ethics committees or country-specific requirements add layers of review. Effective change management and early, local regulatory intelligence are essential to avoid delays and misalignment.
Future impact:
Over the next five years, regulatory complexity will multiply for global trials and multi-region submissions. Companies will need to invest in agile dossier models, digital platforms and continuous learning for regulatory teams. Regulatory agility will become a competitive differentiator. Those who engage early with scientific advice, build regional partnerships and embed flexibility into their development plans will be best positioned to navigate this evolving landscape.
2. Integration of real-world evidence and digital data
Core Challenge: Turning data abundance into validated, regulator-ready evidence.
The integration of RWE and digital data into regulatory decision-making is accelerating. The FDA, EMA and NMPA are actively developing frameworks to incorporate RWE into submissions, while payers and HTA bodies increasingly demand outcomes-based evidence. The ICH M14 guideline, adopted in September 2025, sets a global standard for pharmacoepidemiological safety studies using real-world data. This marks a pivotal shift toward harmonised expectations for evidence quality, protocol pre-specification and statistical rigour.
What’s Happening Now:
Dynamic evidence packages encompassing combining clinical trial data, RWE and digital biomarkers, are becoming the norm. However, the reality is often messy: data not designed for research, lack of harmonisation and access restrictions (such as those seen with federated data networks in Europe) remain major hurdles. Regulators are tightening expectations around data provenance, algorithm explainability and patient privacy.
Practical Perspective:
Sponsors are finding that building compliant, cross-border evidence ecosystems requires cross-functional collaboration while regulatory, HEOR, data science and operations must work together from the outset. There is growing recognition that regulatory strategy must include advocacy for data standardisation and access, as well as a willingness to experiment and adapt as the field evolves.
Future Impact:
By 2030, RWE will underpin not only regulatory submissions but also post-market surveillance, label expansions and reimbursement decisions. Companies will need to embed data science and regulatory affairs functions together, ensuring that evidence generation is both scientifically sound and regulator-ready. The convergence of regulatory and HTA expectations will require integrated strategies that align clinical, economic and humanistic outcomes.
3. Oversight of AI, advanced manufacturing and novel modalities
Core Challenge: Regulatory frameworks lagging behind the pace of scientific innovation.
AI is transforming drug discovery, development and manufacturing. Yet, regulatory oversight is still catching up. In January 2025, the FDA released draft guidance proposing a risk-based credibility framework for AI models used in regulatory decision-making. The EU’s AI Act, fully applicable by August 2027, classifies healthcare-related AI systems as “high-risk”, imposing stringent requirements for validation, traceability and human oversight.
What’s Happening Now:
Regulators are issuing early guidance on AI-enabled device software, continuous manufacturing and advanced therapies such as ATMPs, gene editing and mRNA platforms. However, global standards remain fragmented. Most organisations are still building the literacy and practical experience needed to unlock AI’s value and there is a need for upskilling, targeted pilots and clear governance.
Practical Perspective:
Early engagement with regulators on AI validation can accelerate approval timelines, but lack of readiness for inspection or compliance can lead to costly delays. Regulatory strategy must now move upstream into R&D itself and include both compliance and capability-building.
Future Impact:
Over the next five years, expect new validation requirements for AI algorithms used in development and quality control and potential audits of AI systems. For advanced therapies, regulators will expand bespoke frameworks addressing manufacturing consistency, long-term follow-up and ethical use. Regulatory professionals must become “AI literate” and able to bridge innovation with assurance.
Conclusion: Regulatory affairs as strategic architect
The regulatory landscape is being rewritten. The most impactful organizations will be those that:
- Anticipate divergence and build agility into their regulatory strategies
- Integrate evidence generation across clinical, digital and real-world domains
- Embed regulatory foresight into innovation pipelines, especially for AI and advanced modalities
- Foster cross-functional and global collaboration to ensure readiness and resilience
Lifecycle regulatory strategy is now a dynamic, strategic discipline, requiring ongoing evidence generation, label adaptation and operational integration across regulatory, quality and supply chain teams. Regulatory professionals are not just supporting execution; they are shaping strategy and the future of healthcare.
The future belongs to those who anticipate, adapt and act with purpose. I invite you to join me in shaping the next era of regulatory strategy—where foresight, agility and partnership unlock innovation and access for patients worldwide.
Elizabeth Madichie is vice president, global regulatory affairs consulting at ICON plc.
Key Regulatory Guidance and Source Documents
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Guidelines. Available at: https://www.ich.org/page/ich-guidelines
- ICH. Guideline for Good Clinical Practice E6(R3). Available at: https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
- ICH. M14 Guideline: General principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines. Available at: https://www.ema.europa.eu/en/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-scientific-guideline
- World Health Organization (WHO). WHO Pharmaceutical Quality Assurance Guidelines, 10th Edition. Available at: https://www.who.int/publications/i/item/9789240099425
- European Medicines Agency (EMA). Artificial Intelligence in Medicines Regulation. Available at: https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/artificial-intelligence
- U.S. Food and Drug Administration (FDA). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological
- European Union. Regulation (EU) 2024/1689: Artificial Intelligence Act. Available at: https://www.aiact-info.eu/full-text-and-pdf-download/
- FDA. Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug
- FDA. Conducting Clinical Trials Using Decentralized Elements. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-clinical-trials-decentralized-elements
- EMA. Advanced Therapy Medicinal Products (ATMPs) Regulation. Available at: https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview
- FDA. Cellular & Gene Therapy Products. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products
- European Union. Regulation (EU) 2017/746: In Vitro Diagnostic Medical Devices Regulation (IVDR). Available at: https://eur-lex.europa.eu/eli/reg/2017/746/oj/eng
- European Commission. Reform of the EU Pharmaceutical Legislation. Available at: https://health.ec.europa.eu/medicinal-products/legal-framework-governing-medicinal-products-human-use-eu/reform-eu-pharmaceutical-legislation_en
- FDA. Accelerated Approval Expedited Program for Serious Conditions. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accelerated-approval-expedited-program-serious-conditions
- National Medical Products Administration (NMPA, China). NMPA Alignment with ICH Standards. Available at: https://english.nmpa.gov.cn/2025-02/19/c_1073538.htm
- Central Drugs Standard Control Organization (CDSCO, India). Regulatory Modernization. Available at: https://cdsco.gov.in/opencms/en/Home/
- Pharmaceuticals and Medical Devices Agency (PMDA, Japan). Regulatory Updates & Early Consideration. Available at: https://www.pmda.go.jp/english/review-services/regulatory-info/0002.html
- Therapeutic Goods Administration (TGA, Australia). Legislative Amendments (2024 Measures). Available at: https://www.tga.gov.au/how-we-regulate/tga-learn/sme-assist/regulation-essentials/legislation/legislation-and-legislative-instruments/therapeutic-goods-legislation-amendment-2024-measures-no-3-regulations-2024
- Agência Nacional de Vigilância Sanitária (ANVISA, Brazil). Sustainability Mandates. Available at: https://www.gov.br/anvisa/pt-br/english
- EMA. Recommendations to Strengthen Supply Chains of Critical Medicinal Products. Available at: https://www.ema.europa.eu/en/documents/other/mssg-recommendations-strengthen-supply-chains-critical-medicinal-products_en.pdf
Filed Under: Uncategorized
